Literature DB >> 10944605

Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.

U Elsässer-Beile1, M Rindsfüser, T Grussenmeyer, W Schultze-Seemann, U Wetterauer.   

Abstract

The mRNA expression of the cytokines IFN-gamma, IL-10 and TNF-alpha and the proapoptotic factor Fas ligand (FasL) was compared in freshly isolated CD4(+)and CD8(+)tumour-infiltrating lymphocytes (TIL) and simultaneously obtained autologous CD4(+)and CD8(+)peripheral blood lymphocytes (PBL) from 20 patients with renal cell carcinomas (RCC). TIL were isolated from mechanically disaggregated tumour material and PBL from peripheral blood by gradient centrifugation. The cells of the interphase were depleted from tumour cells with anti-human epithelial antigen magnetic beads and then positive selection was performed with anti-CD4 or anti-CD8 magnetic beads. In these pure lymphocyte preparations the constitutive expression of cytokine and FasL mRNAs was determined by using a PCR-assisted mRNA amplification assay. In the CD4(+)TIL from the 20 patients with RCC, levels of mRNAs encoding for IFN-gamma (P</= 0.001), IL-10 (P</= 0.05), and FasL (P</= 0.001) were significantly higher than in the autologous CD4(+)PBL. Comparison of CD8(+)TIL and CD8(+)PBL revealed a significant higher expression of IFN-gamma (P</= 0.001), IL-10 (P</= 0.01) and FasL mRNAs (P</= 0.001) in the former. However, TNF-alpha mRNA levels were significantly lower in the CD8(+)TIL than in the CD8(+)PBL (P</= 0.05). These data reflect a general in vivo activation of RCC infiltrating lymphocytes in the tumour surrounding. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944605      PMCID: PMC2363516          DOI: 10.1054/bjoc.2000.1275

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; A Anel; A Piñeiro; J Naval
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.

Authors:  N Brouwenstijn; B Gaugler; K M Krüse; C W van der Spek; A Mulder; S Osanto; B J van den Eynde; P I Schrier
Journal:  Int J Cancer       Date:  1996-10-09       Impact factor: 7.396

Review 3.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.

Authors:  U Elsässer-Beile; T Grussenmeyer; D Gierschner; B Schmoll; W Schultze-Seemann; U Wetterauer; J Schulte Mönting
Journal:  Cancer Immunol Immunother       Date:  1999-07       Impact factor: 6.968

5.  Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity.

Authors:  E Angevin; F Kremer; C Gaudin; T Hercend; F Triebel
Journal:  Int J Cancer       Date:  1997-07-29       Impact factor: 7.396

6.  Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts.

Authors:  C Olive; D Nicol; M C Falk
Journal:  Cancer Immunol Immunother       Date:  1997-03       Impact factor: 6.968

7.  Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion.

Authors:  U Elsässer-Beile; U Wetterauer; W Schultze-Seemann; H Gallati; J S Mönting; S von Kleist
Journal:  Cancer Immunol Immunother       Date:  1996-02       Impact factor: 6.968

8.  Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.

Authors:  D Mitropoulos; S Kooi; J Rodriguez-Villanueva; C D Platsoucas
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

9.  Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.

Authors:  J H Finke; P Rayman; L Hart; J P Alexander; M G Edinger; R R Tubbs; E Klein; L Tuason; R M Bukowski
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-02

10.  Fas ligand mediates activation-induced cell death in human T lymphocytes.

Authors:  M R Alderson; T W Tough; T Davis-Smith; S Braddy; B Falk; K A Schooley; R G Goodwin; C A Smith; F Ramsdell; D H Lynch
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more
  1 in total

1.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.